AI analysis for enhanced 3D screening assay data capture

Image-based high-content screening (HCS) is an effective drug discovery approach that measures cellular changes to assess medication effects.

Image Credit: Molecular Devices

Image Credit: Molecular Devices

With the increased interest in 3D biological models, researchers need an imaging platform that can provide high-throughput, high-quality imaging and advanced analytics.

This scientific poster presents the most recent addition to Molecular Devices UK Ltd.’s high-content imaging portfolio: the ImageXpress® HCS.ai High-Content Screening System. This system combines AI-driven software, modular hardware, and cutting-edge optics to improve speed, precision, and flexibility.

The poster uses 3D models to demonstrate the HCS.ai system’s capabilities, extracting multiparametric data and improving analysis accuracy through deep-learning segmentation.

The HCS.ai system accelerates research and provides deeper insights into drug discovery by combining high-throughput acquisition, deep tissue imaging, and AI-powered insights.

Download the Poster

About Molecular Devices

Molecular Devices is one of the world’s leading providers of high-performance life science technology. We make advanced scientific discovery possible for academia, pharma, and biotech customers with platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. From cancer to COVID-19, we've contributed to scientific breakthroughs described in over 230,000 peer-reviewed publications.

Over 160,000 of our innovative solutions are incorporated into laboratories worldwide, enabling scientists to improve productivity and effectiveness – ultimately accelerating research and the development of new therapeutics. Molecular Devices is headquartered in Silicon Valley, Calif., with best-in-class teams around the globe. Over 1,000 associates are guided by our diverse leadership team and female president that prioritize a culture of collaboration, engagement, diversity, and inclusion.

To learn more about how Molecular Devices helps fast-track scientific discovery, visit www.moleculardevices.com.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jun 4, 2025 at 5:51 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Molecular Devices UK Ltd. (2025, June 04). AI analysis for enhanced 3D screening assay data capture. News-Medical. Retrieved on June 05, 2025 from https://www.news-medical.net/whitepaper/20250604/AI-analysis-for-enhanced-3D-screening-assay-data-capture.aspx.

  • MLA

    Molecular Devices UK Ltd. "AI analysis for enhanced 3D screening assay data capture". News-Medical. 05 June 2025. <https://www.news-medical.net/whitepaper/20250604/AI-analysis-for-enhanced-3D-screening-assay-data-capture.aspx>.

  • Chicago

    Molecular Devices UK Ltd. "AI analysis for enhanced 3D screening assay data capture". News-Medical. https://www.news-medical.net/whitepaper/20250604/AI-analysis-for-enhanced-3D-screening-assay-data-capture.aspx. (accessed June 05, 2025).

  • Harvard

    Molecular Devices UK Ltd. 2025. AI analysis for enhanced 3D screening assay data capture. News-Medical, viewed 05 June 2025, https://www.news-medical.net/whitepaper/20250604/AI-analysis-for-enhanced-3D-screening-assay-data-capture.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.